tiprankstipranks
Advertisement
Advertisement

NPCE Stock Latest News

NeuroPace Earnings Call Highlights Growth And AI Push
Company AnnouncementsNeuroPace Earnings Call Highlights Growth And AI Push
11d ago
NPCE
NeuroPace assumed with an Overweight at Wells Fargo
PremiumThe Fly
NeuroPace assumed with an Overweight at Wells Fargo
26d ago
NPCE
NeuroPace: Strong 2025 Execution, Reimbursement Tailwinds, and Label Expansion Upside Support Reiterated Buy and $19 Target
PremiumRatings
NeuroPace: Strong 2025 Execution, Reimbursement Tailwinds, and Label Expansion Upside Support Reiterated Buy and $19 Target
1M ago
NPCE
Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access
PremiumCompany Announcements
Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access
1M ago
NPCE
NeuroPace reports Q4 EPS (8c), consensus (17c)
PremiumThe Fly
NeuroPace reports Q4 EPS (8c), consensus (17c)
1M ago
NPCE
NeuroPace sees Q1 revenue $21M-$22M, consensus $21.93M
PremiumThe FlyNeuroPace sees Q1 revenue $21M-$22M, consensus $21.93M
1M ago
NPCE
NeuroPace sees FY26 revenue $98M-$100M, consensus $98.94M
Premium
The Fly
NeuroPace sees FY26 revenue $98M-$100M, consensus $98.94M
1M ago
NPCE
NPCE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
NPCE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
NPCE
NeuroPace price target raised to $19 from $18 at H.C. Wainwright
PremiumThe Fly
NeuroPace price target raised to $19 from $18 at H.C. Wainwright
3M ago
NPCE
Morning Movers: L3Harris Technologies jumps after DoW investment
PremiumThe Fly
Morning Movers: L3Harris Technologies jumps after DoW investment
3M ago
BK
CAH
NeuroPace sees FY26 revenue $98M-$100M, consensus $98.44M
PremiumThe Fly
NeuroPace sees FY26 revenue $98M-$100M, consensus $98.44M
3M ago
NPCE
NeuroPace sees Q1 revenue $21M-$22M, consensus $22.35M
PremiumThe Fly
NeuroPace sees Q1 revenue $21M-$22M, consensus $22.35M
3M ago
NPCE
NeuroPace reports preliminary Q4 revenue $26.6M, consensus $24.43M
PremiumThe FlyNeuroPace reports preliminary Q4 revenue $26.6M, consensus $24.43M
3M ago
NPCE
NeuroPace Initiated With Buy on Breakthrough RNS Label Expansion Opportunity and Strong NAUTILUS Efficacy Data
Premium
Ratings
NeuroPace Initiated With Buy on Breakthrough RNS Label Expansion Opportunity and Strong NAUTILUS Efficacy Data
4M ago
NPCE
NeuroPace files premarket approval supplement application for RNS System
Premium
The Fly
NeuroPace files premarket approval supplement application for RNS System
4M ago
NPCE
NeuroPace price target raised to $22 from $18 at UBS
PremiumThe Fly
NeuroPace price target raised to $22 from $18 at UBS
4M ago
NPCE
NeuroPace price target raised to $20 from $18 at JPMorgan
PremiumThe Fly
NeuroPace price target raised to $20 from $18 at JPMorgan
4M ago
NPCE
Buy Rating Affirmed on Promising NAUTILUS Trial Results and Potential FDA Consideration
PremiumRatings
Buy Rating Affirmed on Promising NAUTILUS Trial Results and Potential FDA Consideration
4M ago
NPCE
NeuroPace presents NAUTILUS trial data at American Epilepsy Society meeting
PremiumThe Fly
NeuroPace presents NAUTILUS trial data at American Epilepsy Society meeting
4M ago
NPCE
NeuroPace announces Medicare reimbursement increases for RNS System
PremiumThe FlyNeuroPace announces Medicare reimbursement increases for RNS System
5M ago
NPCE
NeuroPace’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating
Premium
Ratings
NeuroPace’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating
5M ago
NPCE
NeuroPace, Inc. Reports Record Revenue and Growth
Premium
Company Announcements
NeuroPace, Inc. Reports Record Revenue and Growth
5M ago
NPCE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >